Table 5.

Prognostic 22-miRNA profile based predictive drug response model performance in the training, test, and osteosarcoma (OSA) cell line sets.

miRNA	drug	MoA	target	coef	training FDR	test cor	test p	OSA cor	n(−) connectivity hits
514a-3p	dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	−0.511	2.25E-08	0.543	6.29E-06	NA	4
514a-3p	vemurafenib	RAF inhibitor	BRAF, RAF1	−0.500	3.48E-08	0.405	3.41E-04	NA	3
514a-3p	cobimetinib	MEK inhibitor	NA	−0.441	1.56E-06	0.418	8.31E-05	NA	3
514a-3p	binimetinib	MEK inhibitor	MAP2K1, MAP2K2	−0.410	2.53E-06	0.389	6.91E-06	0.353	NA
514a-3p	TAK-733	MEK inhibitor	MAP2K1	−0.397	4.13E-06	0.254	0.004	0.766	5
514a-3p	Ro-4987655	MEK inhibitor	MAP2K1	−0.397	4.13E-06	0.349	5.83E-05	0.214	1
514a-3p	PD-0325901	MEK inhibitor	MAP2K1	−0.352	2.25E-04	0.221	0.015	0.445	11
125b-5p	CGS-15943	adenosine receptor antagonist	ADORAI, ADORA2A, ADORA2B, ADORA3	0.135	3.99E-04	0.301	0.004	NA	3
125b-5p	tetrandrine	calcium channel blocker	SLC6A3	0.105	0.002	0.255	0.003	0.468	0
125b-5p	LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR	−0.103	0.002	0.254	0.003	0.230	NA
514a-3p	CNX-774	Bruton’s tyrosine kinase (BTK) inhibitor	BTK	−0.330	0.003	0.352	4.70E-04	NA	0
514a-3p	RAF265	RAF inhibitor, VEGFR inhibitor	BRAF	−0.326	0.004	0.356	1.03E-04	NA	NA
125b-5p	fluvastatin	HMGCR inhibitor	HMGCR	−0.097	0.005	0.178	0.038	0.053	0
125b-5p	neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	0.108	0.009	0.345	3.63E-04	0.165	8
514a-3p	AS-703026	MEK inhibitor	MAP2K1, MAP2K2	−0.315	0.010	0.399	1.18E-04	NA	3
125b-5p	tucatinib	EGFR inhibitor	ERBB2	0.099	0.025	0.326	0.001	0.656	NA
514a-3p	ABT-702	adenosine kinase inhibitor	ADK	−0.305	0.031	0.388	1.61E-04	NA	3
514a-3p	PD-318088	MEK inhibitor	MAP2K1	−0.273	0.039	0.345	3.59E-04	0.671	NA
514a-3p	GDC-0879	RAF inhibitor	BRAF	−0.337	0.048	0.623	0.001	NA	10